Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Acute 8Leukemia 7Burkitt Lymphoma 7Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 6Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 5Lymphoma 5Lymphoma, B-Cell, Marginal Zone 4Leukemia, Prolymphocytic 4Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Congenital Abnormalities 3Primary Myelofibrosis 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Tumor Lysis Syndrome 1Small Cell Lung Carcinoma 1Sezary Syndrome 1

Interventions

rasburicase 5Uric Acid 1Urate Oxidase 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Tumor Lysis Syndrome × Allopurinol × Clear all
NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

M.D. Anderson Cancer Center

Phase 2 Completed
55 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡